These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

175 related articles for article (PubMed ID: 17338641)

  • 1. Effects of disease-modifying anti-rheumatic drugs (DMARDs) on the activities of rheumatoid arthritis-associated cathepsins K and S.
    Weidauer E; Yasuda Y; Biswal BK; Cherny M; James MN; Brömme D
    Biol Chem; 2007 Mar; 388(3):331-6. PubMed ID: 17338641
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The role of cathepsins in osteoporosis and arthritis: rationale for the design of new therapeutics.
    Yasuda Y; Kaleta J; Brömme D
    Adv Drug Deliv Rev; 2005 May; 57(7):973-93. PubMed ID: 15876399
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Current concepts in clinical therapeutics: disease-modifying drugs for rheumatoid arthritis.
    Pugh MC; Pugh CB
    Clin Pharm; 1987 Jun; 6(6):475-91. PubMed ID: 3319362
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effect of antirheumatic drugs on proteinases in synovia of patients with rheumatoid arthritis.
    Haataja M; Fräki JE; Vainio E
    Int J Clin Pharmacol Biopharm; 1978 Sep; 16(9):417-9. PubMed ID: 700914
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Mechanism of action of the disease-modifying anti-arthritic thiol agents D-penicillamine and sodium aurothiomalate: restoration of cellular free thiols and sequestration of reactive aldehydes.
    Wood PL; Khan MA; Moskal JR
    Eur J Pharmacol; 2008 Feb; 580(1-2):48-54. PubMed ID: 18022616
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cathepsin K inhibitor-polymer conjugates: potential drugs for the treatment of osteoporosis and rheumatoid arthritis.
    Wang D; Li W; Pechar M; Kopecková P; Brömme D; Kopecek J
    Int J Pharm; 2004 Jun; 277(1-2):73-9. PubMed ID: 15158970
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of antirheumatic drugs on cathepsin B1 from bovine spleen.
    Kruze K; Fehr K; Böni A
    Z Rheumatol; 1976; 35(3-4):95-102. PubMed ID: 817531
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Disease modifying anti-rheumatic drugs (DMARDs): an overview].
    Kawabata D; Mimori T
    Nihon Rinsho; 2005 Jan; 63 Suppl 1():489-92. PubMed ID: 15799404
    [No Abstract]   [Full Text] [Related]  

  • 9. Drug delivery strategies for cathepsin inhibitors in joint diseases.
    Wang D; Brömme D
    Expert Opin Drug Deliv; 2005 Nov; 2(6):1015-28. PubMed ID: 16296806
    [TBL] [Abstract][Full Text] [Related]  

  • 10. An evidence-based assessment of the clinical significance of drug-drug interactions between disease-modifying antirheumatic drugs and non-antirheumatic drugs according to rheumatologists and pharmacists.
    van Roon EN; van den Bemt PM; Jansen TL; Houtman NM; van de Laar MA; Brouwers JR
    Clin Ther; 2009 Aug; 31(8):1737-46. PubMed ID: 19808132
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Biochemical properties and regulation of cathepsin K activity.
    Lecaille F; Brömme D; Lalmanach G
    Biochimie; 2008 Feb; 90(2):208-26. PubMed ID: 17935853
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Identification of a potent and selective non-basic cathepsin K inhibitor.
    Li CS; Deschenes D; Desmarais S; Falgueyret JP; Gauthier JY; Kimmel DB; Léger S; Massé F; McGrath ME; McKay DJ; Percival MD; Riendeau D; Rodan SB; Thérien M; Truong VL; Wesolowski G; Zamboni R; Black WC
    Bioorg Med Chem Lett; 2006 Apr; 16(7):1985-9. PubMed ID: 16413777
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Treatment of patients with rheumatoid arthritis with DMARD (disease modifying anti-rheumatic drugs)].
    Halberg P
    Ugeskr Laeger; 1984 Jul; 146(27):1995-2000. PubMed ID: 6440327
    [No Abstract]   [Full Text] [Related]  

  • 14. [Prevention of joint destruction by osteoclast-targeting therapy in search of new tools, such as OPG or cathepsin K inhibitor].
    Kadono Y; Tanaka S
    Clin Calcium; 2009 Mar; 19(3):387-93. PubMed ID: 19252249
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Novel, potent P2-P3 pyrrolidine derivatives of ketoamide-based cathepsin K inhibitors.
    Barrett DG; Catalano JG; Deaton DN; Hassell AM; Long ST; Miller AB; Miller LR; Ray JA; Samano V; Shewchuk LM; Wells-Knecht KJ; Willard DH; Wright LL
    Bioorg Med Chem Lett; 2006 Mar; 16(6):1735-9. PubMed ID: 16376075
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pivotal advance: inhibition of HMGB1 nuclear translocation as a mechanism for the anti-rheumatic effects of gold sodium thiomalate.
    Zetterström CK; Jiang W; Wähämaa H; Ostberg T; Aveberger AC; Schierbeck H; Lotze MT; Andersson U; Pisetsky DS; Erlandsson Harris H
    J Leukoc Biol; 2008 Jan; 83(1):31-8. PubMed ID: 17913975
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Primary amides as selective inhibitors of cathepsin K.
    Léger S; Bayly CI; Black WC; Desmarais S; Falgueyret JP; Massé F; Percival MD; Truchon JF
    Bioorg Med Chem Lett; 2007 Aug; 17(15):4328-32. PubMed ID: 17544269
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Aurothiomalate inhibits COX-2 expression in chondrocytes and in human cartilage possibly through its effects on COX-2 mRNA stability.
    Nieminen R; Vuolteenaho K; Riutta A; Kankaanranta H; van der Kraan PM; Moilanen T; Moilanen E
    Eur J Pharmacol; 2008 Jun; 587(1-3):309-16. PubMed ID: 18448096
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Differential influences of gold sodium thiomalate and bucillamine on the generation of CD14+ monocyte-lineage cells from bone marrow of rheumatoid arthritis patients.
    Hirohata S; Yanagida T; Hashimoto H; Tomita T; Ochi T; Nakamura H; Yoshino S
    Clin Immunol Immunopathol; 1997 Sep; 84(3):290-5. PubMed ID: 9281388
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Rational design of potent and selective NH-linked aryl/heteroaryl cathepsin K inhibitors.
    Robichaud J; Bayly C; Oballa R; Prasit P; Mellon C; Falgueyret JP; Percival MD; Wesolowski G; Rodan SB
    Bioorg Med Chem Lett; 2004 Aug; 14(16):4291-5. PubMed ID: 15261289
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.